A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of Flufirvitide-3 Nasal Spray in Healthy Subjects.

Next Previous
Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of Flufirvitide-3 Nasal Spray in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2012

At a glance

  • Drugs Flufirvitide-3 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions

    • Most Recent Events

    • 13 Jan 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
    • 13 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top